Locus-bio.com Website Review

crispr-engineered precision antibacterial platform to revolutionize the treatment of disease. locus biosciences is a biotechnology company that develops crispr-engineered precision antibacterial products. our crispr-phage (“crphage”) platform combines the antibacterial power of crispr-cas3 with the efficient, safe delivery of bacterial by selectively removing unwanted bacteria while leaving the many species of good bacteria intact, crphage™ can address the growing set of diseases shown to be related to the human microbiome. crphage™ is designed to rapidly respond to emerging antibiotic resistant pathogenic threats at the site of infection. a high-throughput discovery automation platform combined with powerful synthetic biology methods cas3 is a powerful exonuclease that shreds dna beyond repair, leading to a target bacteria cell’s rapid elimination bacteriophages, or “phages,” are naturally-occurring viruses that target and eliminate bacteria. locus biosciences’ crphage™ platform has the potential to revolutionize medical science in two critical areas. the second area is microbiome-related disease. our additional crphage™ programs are aimed at undisclosed bacterial targets relevant for inflammatory bowel disease (ibd) and other disorders causes by dysbiosis of the microbiome in gastrointestinal, immunology, learn how our crphage™ platform technology kills pathogenic bacteria, including antibiotic-resistant “superbugs.” see why our crphage™ platform technology is the world’s most effective therapy for selectively removing bacteria from the body to. locus biosciences has as*embled an experienced team of leaders in crispr, antibacterial drug development, and biotech finance to drive. nick taylor is a co-founder of locus biosciences and is a member of the project management office.  he earned a master's of microbial biotechnology and an mba in technology commercialization & entrepreneurship at north carolina state university. previously, nick